CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Creative Medical Technology Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Creative Medical Technology Holdings Inc
211 E. Osborn Rd.
Phone: (480) 399-2822p:480 399-2822 PHOENIX, AZ  85012  United States Ticker: CELZCELZ

Business Summary
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company. The Company is focused on the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. The Company conducts its commercial operations through its subsidiary, Creative Medical Technologies, Inc. (CMT). CMT markets and sells its CaverStem and FemCelz disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. The CaverStem and FemCelz kits are available through physicians at eight locations in the United States. Its products include StemSpine, ImmCelz, and OvaStem. StemSpine is a regenerative stem cell procedure for the treatment of degenerative disc disease. ImmCelz is a universal donor stem cell therapy for stroke treatment. OvaStem is a stem cell therapy for premature ovarian failure.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director TimothyWarbington 62 5/18/2016 5/18/2016
Chief Financial Officer, Senior Vice President, Director DonaldDickerson 58 5/18/2016 5/18/2016
Independent Director Michael H.Finger 76 12/2/2021 12/2/2021
Independent Director SusanSnow 66 12/2/2021 12/2/2021
Independent Director Bruce S.Urdang 65 12/2/2021 12/2/2021

Business Names
Business Name
AmnioStem LLC
CELZ
CELZD
5 additional Business Names available in full report.

General Information
Number of Employees: 4 (As of 12/31/2023)
Outstanding Shares: 1,356,626 (As of 3/22/2024)
Shareholders: 75
Stock Exchange: NASD
Federal Tax Id: 870622284


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024